XML 22 R4.htm IDEA: XBRL DOCUMENT v3.24.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
 3 Months Ended
Nov. 30, 2024
Nov. 30, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)    
Revenue $ 183,923 $ 151,278
Cost of goods sold 2,720 4,822
Gross profit 181,203 146,456
Operating expenses    
Research and development 1,953,220 574,491
General and administrative 918,690 711,107
Total operating expenses 2,871,910 1,285,598
Loss from operations (2,690,707) (1,139,142)
Other income (loss)    
Interest income 11 7,319
Unrealized loss on marketable securities (15,932) (53,215)
Total other income (loss) (15,921) (45,896)
Net loss (2,706,628) (1,185,038)
Less: Net loss attributable to non-controlling interest (2,929) (5,715)
Net loss attributable to Lexaria shareholders (2,703,699) (1,179,323)
Other comprehensive income    
Foreign currency translation adjustment (3,175) 4,372
Total comprehensive loss $ (2,706,874) $ (1,174,951)
Basic and diluted loss per share $ (0.16) $ (0.13)
Weighted average number of common shares outstanding    
- Basic and diluted 16,668,513 9,051,531